2 Stocks That Have More Than Doubled in the Past Year to Buy and Hold for a Decade

Listen up, folks! The market's been a rollercoaster this year, with the S&P 500 down nearly 1.5% over the trailing-12-month period and a massive 13.8% drop so far this year. But don't let that scare you away from some incredible opportunities. Today, we're diving into two stocks that have more than doubled in the past year and are poised to deliver strong returns for the next decade. Let's get started!



Summit Therapeutics (SMMT): The Biotech Powerhouse

First up, we have Summit Therapeutics, a clinical-stage biotech company with a market cap of $15.1 billion. That's right, folks, a biotech company without a single product on the market has a valuation that's through the roof! Why? Because their leading candidate, ivonescimab, is a game-changer.

Ivonescimab has already shown strong clinical results, beating Keytruda, the world's best-selling medicine, in a phase 3 study for non-small cell lung cancer. This drug has the potential to earn a slew of approvals across various types of cancer, making Summit Therapeutics a "pipeline in a drug." More clinical and regulatory wins for ivonescimab could jolt the stock price and allow Summit Therapeutics to generate growing revenue. This company has yet to peak, and it could still deliver excellent returns in the next decade.

Robinhood Markets (HOOD): The Investment Revolution

Next, we have Robinhood Markets, the investment platform that's revolutionizing the way younger generations invest. Robinhood delivered blowout financial results last year, with revenue increasing by 58% year over year to $2.95 billion. The company showed green on the bottom line in every quarter last year, with full-year net earnings per share of $1.56, compared to a loss per share of $0.61 reported in the previous fiscal year.

Robinhood is no longer just the platform of choice for newbie investors. It's a full-fledged financial services provider with a range of growth opportunities. The company's subscription service, Robinhood Gold, ended the year with 2.6 million members, and it's ramping up its suite of new products, including the launch of Robinhood Legend and the acquisition of TradePMR. Robinhood is a no-brainer buy-and-hold stock for the next decade.



Why These Stocks Are Buy-and-Hold Winners

Both Summit Therapeutics and Robinhood Markets have shown exceptional performance in the past year, and their future growth potential is immense. Summit Therapeutics' ivonescimab has the potential to revolutionize cancer treatment, while Robinhood Markets is poised to benefit from the Great Wealth Transfer, where more than $50 trillion in wealth will be passed from baby boomers to younger generations over the next few decades.

So, don't miss out on these incredible opportunities! Buy and hold these stocks for the next decade, and you'll be thanking yourself later. The market may be volatile, but these two stocks are poised for long-term growth. BUY NOW!